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The broad repertoire of secreted trophic and immunomodulatory cytokines produced bymesenchymal stem
cells (MSCs), generally referred to as the MSC secretome, has considerable potential for the treatment of
cardiovascular disease. However, harnessing this MSC secretome for meaningful therapeutic outcomes is
challenging due to the limited control of cytokine production following their transplantation. This review
outlines the current understanding of the MSC secretome as a therapeutic for treatment of ischemic heart
disease. We discuss ongoing investigative directions aimed at improving cellular activity and characterizing
the secretome and its regulation in greater detail. Finally, we provide insights on and perspectives for future
development of the MSC secretome as a therapeutic tool.Introduction
Ischemic heart disease is the leading cause of human mortality
globally, resulting in about 7.25 million deaths each year (World
Health Organization, 2011). Acute myocardial infarction (AMI) is
the most common cause of heart failure. AMI triggers a series
of cellular andmolecular changes leading to apoptosis, necrosis,
and hypertrophy of cardiomyocytes; impaired neovasculariza-
tion; interstitial fibrosis and inflammation; reduced contractility;
and pathological remodeling. Current therapies have failed to
address the devastating aftermath of AMI. Most clinically
approved therapeutics focus on modulating hemodynamics to
reduce early mortality but do not facilitate cardiac repair in the
way that would be needed to reduce the incidence of heart
failure (Velagaleti et al., 2008). It is now widely accepted that
treatment of the complex pathology resulting from AMI will
require taking approaches designed to enhance tissue regener-
ation via cell transplantation or co-opting local mechanisms that
promote healing and inhibit pathological remodeling (Wollert and
Drexler, 2010).
Regeneration of an infarcted heart necessitates massive cell
replenishment, possibly in the order of a billion cardiomyocytes,
and functional integration together with supporting cell types
(Laflamme and Murry, 2005). While the search for cardiac-
progenitor cells (CPCs) that can readily engraft within damaged
tissue and differentiate into functioning cardiomyocytes
continues (Xu et al., 2011), regenerative therapy using bone-
marrow-derived mononuclear cells (BM-MNCs) and mesen-
chymal stem cells (MSCs) has shown considerable promise in
preclinical studies (Chavakis et al., 2010; Mirotsou et al., 2011).
The first stem-cell-based clinical trials for MI (initiated between
2002 and 2005) used unfractionated, easily accessible, and
highly heterogeneous adult BM-MNCs. Despite initial positive
results indicating safety of BM-MNC transplantation and244 Cell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc.improved cardiac function, the differences in trial design, treat-
ment methods, outcome evaluation, and cell isolation have
prevented general conclusions, and all of these studies require
long-term follow-up analysis (Wollert and Drexler, 2010).
Recent clinical trials have looked at relatively homogenous
MSCs expanded in culture after isolation from bone marrow
(containing 0.001%–0.01% MSCs) as potential cell therapy
candidates for AMI owing to their immunomodulatory properties,
ready availability, and cardiac stem cell (CSC) niche-regulatory
ability. The first clinical trial for AMI using human MSCs (hMSCs)
demonstrated the safety of hMSC transplantation and provi-
sional efficacy (Hare et al., 2009). However, the improved cardiac
function observed in preclinical studies is without long-term
MSC engraftment (Iso et al., 2007), and, in animal studies,
systemically administered MSCs exhibit low (2%) engraft-
ment levels and limited capacity for transdifferentiation into
cardiomyocytes posttransplantation (Leiker et al., 2008). Thus,
it seems unlikely that MSCs contribute directly to replenishing
cardiomyocyte populations in the heart, and this notion moti-
vated MSC-induced immunomodulatory and remodeling effects
to be proposed as mechanisms of cardiovascular repair.
Although the trophic and immunomodulatory properties of
MSCs represent a primary mechanism of therapeutic action
that is referred to in many current clinical trials (Ankrum and
Karp, 2010; Wollert and Drexler, 2010), it is important to note
that these functions of MSCs have not yet been optimized in
preclinical models to maximize their therapeutic potential.
The spectrum of regulatory and trophic factors secreted by
MSCs, including growth factors, cytokines, and chemokines,
is broadly defined as the MSC secretome. A thorough in vivo
examination of this MSC secretome and strategies to modulate
it are still lacking, but seem essential for rational therapy design
and improvement of existing therapies. Despite the absence of
Figure 1. A Proposed Approach for Small-
Molecule-Mediated Regulation of the MSC
Secretome
(A) Conditioning MSCs with small molecules can
stimulate the production of a customized secre-
tome that can be optimized and characterized
in vitro.
(B) The effect of small molecule conditioning of
MSCs can be tested under highly dynamic,
simulated conditions, mimicking microenviron-
ments before and after the onset of MI, and this
may include coculture assays with hypoxic
cardiomyocytes and inflammatory cells. Proin-
flammatory cytokines such as TNF-a and IL-6 can
be introduced to anMSC culture, for example, and
MSC-secreted factors (in blue) such as sTNFR1
and IL-10 can be tracked, as can their ability to
modulate the release of inflammatory cytokines
from activated leukocytes. MSCs may secrete
molecules such as IDO and PGE2 that induce
leukocytes to produce anti-inflammatory cyto-
kines such as IL-10 that attenuate the effects of
activated leukocytes and inhibit the proin-
flammatory activity of constitutively secreted IL-6
(from MSCs) and/or IL-6 already expressed in the
myocardium. Likewise, to attenuate pathological
remodeling, one can test if small molecules can
boost MSC secretion of TIMP-1 to inhibit ECM-
degrading proteases such as MMP-9. In addition
to paracrine effects, conditioned MSCs may act
through autocrine signaling to improve cell
survival in hypoxic conditions.
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some promise in preclinical models. In these cases the secre-
tome was modulated by physiological (hypoxic or anoxic),
pharmacological (small molecule), cytokine, or growth factor
preconditioning and/or genetic manipulations (Afzal et al.,
2010; Kamota et al., 2009; Shi et al., 2009; Tang et al., 2010)
prior to transplantation. Nevertheless, several questions
regarding MSC secretome function and regulation remain un-
answered, including the following: (1) what are the most effec-
tive approaches to study the MSC secretome in vivo, and are
new technologies required to achieve this? (2) How do the
properties of the MSC secretome (composition and sustain-
ability) change in vitro and after transplantation, and how
does it evolve as a function of the dynamic local microenviron-
ment? (3) What are the best methods to achieve sustainability
of the secretome and control over its composition posttrans-
plantation?
Here we discuss current understanding of theMSC secretome
and put in perspective its application to cardiovascular therapy.
We also review tools for MSC secretome profiling and current
preconditioning strategies that aim to transiently control the
secretome posttransplantation. Finally, we suggest approaches
that could exploit the MSC secretome for cardiovascular
therapy.Cell Stem CellProfiling theMSCSecretome: Tools
and Critical Parameters
To define the specific roles of MSC-
secreted factors in cardiovascular
regeneration, one should start with bio-
molecular profiling or secretome analysis
of cultured primary MSCs (Figure 1A). Atypical MSC secretion profile comprises growth factors, cyto-
kines, extracellular matrix (ECM) proteases, hormones, and lipid
mediators (typically in low abundance). Thus, MSC in vitro secre-
tome analysis must consider the effect of serum, which contains
many overlapping components and can interfere with detection.
To circumvent this problem, MSCs can be cultured for a short
time frame in serum-free medium or medium with defined serum
replacements. It is critical to consider that secretome expression
in vitro is likely very different fromwhat would be expected in vivo
where cells within different microenvironments would exhibit
unique secretome expression profiles. Conversely, as microen-
vironments are highly dynamic, they would in turn impact the
kinetics of secretome expression. Thus, moving forward it will
be critical to examine secretome expression in vitro under condi-
tions that model several relevant in vivo microenvironments.
The tools available for studying secretome expression in vitro
include multiplex antibody-based techniques, such as antibody
arrays that offer high sensitivity (typically 1–10 pg/ml) as well as
high specificity, reproducibility across a broad range of concen-
trations, and the potential for massively parallel experimentation.
High-throughput analysis of the hMSC secretome using a human
cytokine antibody array, for example, identified at least 40
proteins with high expression levels varying from 10% to 110%
spot intensity relative to the negative control and normalized to10, March 2, 2012 ª2012 Elsevier Inc. 245
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also been employed to assess the contribution of MSC-derived
factors such as VEGF, TIMP-1, TIMP-2, and TSP-1 in cardiac
improvement in swine MI models (Nguyen et al., 2010). The
impact of hMSC tissue origin on secretome characteristics
(bone marrow versus umbilical cord) has also been examined
(Park et al., 2009) using antibody arrays. IL-8 was secreted at
higher concentrations in umbilical-cord-blood-derived-MSCs
(UCB-MSCs), while IGBP class cytokines were specific to
UCB-MSCs compared with BM-MSCs, indicating a potential
origin-specific hMSC secretome.
In addition to antibody-based approaches, Liquid Chroma-
tography with Tandem Mass Spectrometry Detection (LC-MS/
MS) is useful for characterizing the secretome profile. For
example, preconditioning of human adipose-tissue-derived
MSCs with TNF-a had a profound impact on the secretome de-
tected using LC-MS/MS (Lee et al., 2010), and led to increased
expression of cytokines and chemokines such as IL-6, IL-8,
MCP-1, MMPs, PTX3, and Cathepsin L. However, LC-MS/MS
was unable to detect many cytokines and growth factors
that were present in low concentrations. A more systematic
integrated approach for hMSC secretome analysis included
LC-MS/MS detection, antibody arrays, microarrays, and bio-
informatics (Sze et al., 2007), and identified 201 unique proteins
(132 using LC-MS/MS and 72 using antibody arrays). Impor-
tantly, Sze et al. used computational analysis to predict the
roles of the secretome components in metabolism, immune
response, and development.
While current techniques have been useful to identify factors
expressed at high levels such as IL-6, IL-8, TIMP-2, VEGF, and
MCP-1, suggesting constitutive secretion from BM-hMSCs
(Park et al., 2009), a complete list of constitutively expressed
MSC secretome factors remains to be generated. Despite recent
advances in the characterization of the MSC secretome, current
techniques suffer from multiple deficiencies. Gel-based and
LC-MS/MS techniques have limited sensitivity to molecules in
low concentrations (10–20 fmol), and antibody-based tech-
niques (e.g., ELISA and antibody arrays) are limited by the
availability of antibodies to detect secreted proteins. Hence,
comprehensive in vitro secretome profiling requires an inte-
grated approach employing multiple techniques. Although
determining the mechanism regulating the expression of the
secretome is important, the task is made more challenging
given that some of the proteins are released during cell death
(Skalnikova et al., 2011). Perhaps the most important goal will
be to move toward methods to profile the secretome in vivo
that can distinguish between factors released from the host
versus those secreted by the transplanted MSCs. Reaching
this point will require the development of new techniques that
can directly quantify the dynamic expression profile of MSC-
secreted factors both locally and systemically.
Close to the Heart? Relevance of MSC Paracrine
Signaling to Cardiovascular Therapy
Recent studies have suggested four potential mechanisms
for how exogenous-culture-expanded MSCs may contribute to
cardiovascular repair: MSC transdifferentiation into cardiomyo-
cytes (Hatzistergos et al., 2010), fusion of MSCs with native cells
(Noiseux et al., 2006), MSC-induced stimulation of endogenous246 Cell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc.CSCs via direct cell-cell interaction (Mazhari and Hare, 2007),
and MSC-paracrine (or endocrine) signaling (Gnecchi et al.,
2005; Lee et al., 2009). MSC transdifferentiation into contractile
cardiomyocytes is inefficient at best (Toma et al., 2002) and
occurs only in the presence of native cardiomyocytes (Hatzister-
gos et al., 2010; Loffredo et al., 2011; Mazhari and Hare, 2007).
Cell fusion is a rare event, which rules out substantial involve-
ment in MSC-mediated cardiovascular regeneration (Loffredo
et al., 2011). Nevertheless, there is strong evidence emerging
that rat BM-derived MSCs (rMSCs) secrete trophic factors that
may induce activation and proliferation of endogenous CPCs
in vitro (Nakanishi et al., 2008). Although it is possible that
resident CSCs may differentiate into mature and functional
cardiomyocytes upon interaction with transplanted MSCs
(Hatzistergos et al., 2010), evidence suggests that CSCs
possess only a limited capacity to differentiate into fully mature
cardiomyocytes with an adult phenotype (Beltrami et al., 2003;
Urbanek et al., 2005). Despite evidence of preferential accumu-
lation of MSCs at sites of myocardial ischemia (Williams and
Hare, 2011), exogenously administered MSCs show poor
survival and do not persist at the site of AMI (Iso et al., 2007;
Terrovitis et al., 2010), probably because of the harsh ischemic
microenvironment, characterized by oxidative stress, inflamma-
tion, cytotoxic cytokines, and in some instances an absence
of ECM for MSC attachment (Rodrigues et al., 2010; Song
et al., 2010). Such a hostile microenvironment could hinder the
interaction of MSCs with endogenous CSCs.
A more plausible explanation for MSC-mediated cardiovas-
cular repair is an effect on host cells and the microenvironment
via MSC-secreted growth factors, cytokines, and other signaling
molecules. This proposal is supported by recent preclinical
studies (Kanki et al., 2011; Timmers et al., 2011) that demon-
strated improved cardiac function upon infusion of cytokines
or MSC-conditioned medium (without cell transplantation)
(Beohar et al., 2010). Therefore, identifying key MSC-secreted
factors and their functional roles in cardiovascular therapies
seems a useful approach for rational design of next-generation
MSC-based therapeutics.
Effects of theMSC Secretome on Cardiovascular Repair
The functional roles reported for MSC-secreted factors are both
impressive and confusing. MSCs are known to be the source of
multiple immunomodulatory agents plus trophic factors involved
in repair and regenerative processes (Nauta and Fibbe, 2007;
van Poll et al., 2008). This broad array of secreted factors
suggests possible stress response regulatory roles for MSCs,
such as homing of c-kit+ cells to injured myocardium (Tang
et al., 2010). It is not known whether cytokines released from
stressed or dying MSCs make a therapeutic contribution. The
hMSC secretome includes multiple factors (Lee et al., 2010; Par-
ekkadan et al., 2007; Park et al., 2009; Sze et al., 2007) known to
promote cardiovascular repair (Table S1 available online) and
factors that negatively modulate cardiomyocyte apoptosis,
inflammation, and pathological remodeling (Table S2). Although
several factors in the MSC secretome have shown utility for
influencing cardiac repair when delivered exogenously in the
absence of MSCs (factors listed in Tables S1 and S2 not marked
by an [*]), it is still critical to demonstrate the direct functionality of
such factors when secreted from MSCs and the potential
synergy that may exist with other secreted factors.
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therapeutic mechanisms offered by MSC secretome compo-
nents spans tissue preservation (antiapoptotic and promitotic),
neovascularization, cardiac remodeling (ECM alteration and
strengthening of the infarct scar), anti-inflammatory responses
(antifibrosis and suppression of inflammatory cells), and the
highly contentious endogenous regeneration (activation of
CPCs and CSCs). MSCs induce myocardial protection by
promoting cardiomyocyte survival and preventing apoptosis
through activation of PKC, PI3K/Akt, NF-kB, and STAT3 sig-
naling (Gnecchi et al., 2008; Mirotsou et al., 2011). In ischemic
animal models, MSCs mediate neovascularization via paracrine
signaling (Kinnaird et al., 2004a, 2004b; Matsumoto et al., 2005;
Tang et al., 2005) and have antiapoptotic, anti-inflammatory,
and antifibrotic effects on cardiomyocytes and endothelial
cells (Bartosh et al., 2010; Berry et al., 2006; Iso et al., 2007;
Lee et al., 2009; Shabbir et al., 2009). MSC-induced immuno-
modulation and antiapoptosis of cardiomyocytes that has
been observed in inflammatory heart diseases such as acute
myocarditis in mice (Van Linthout et al., 2011) and sepsis in
rats (Weil et al., 2010) are likely mediated via paracrine effects.
In addition, MSCs exert immunomodulatory effects by inducing
neighboring cells to secrete relevant cytokines (Aggarwal and
Pittenger, 2005; Franc¸ois et al., 2012; Ne´meth et al., 2009;
Prockop and Oh, 2012), which may be useful in inhibiting
excessive inflammation and pathological remodeling under MI
settings.
MSC Homing to the Injured Myocardium: The Role
of MSC Secretome
There is significant debate about whether MSCs need to engraft
at the target site of injury or can exert their effects systemically.
Engraftment at the target site would in principle seem beneficial
due to the potential for cell-cell contact and increased concen-
trations of immunomodulatory and trophic factors. In the context
of cell homing following systemic infusion, sites of MI exhibit
increased expression and secretion of selective chemokines,
cytokines, and cell adhesion molecules, including ICAM-1,
IL-6, SDF-1, VCAM-1, and FN-1 (Ip et al., 2007). However,
culture-expanded MSCs exhibit limited homing capacity, prob-
ably because of poor expression of receptors for chemokines
and adhesion ligands such as CXCR4 and CCR1. As the number
of transplanted MSCs homing to the infarcted heart rapidly
declines following intravenous infusion (Assis et al., 2010) due
to entrapment in the microvasculature, there is a significant
need to improve circulation times and homing efficiency of
systemically administered cells (Karp and Leng Teo, 2009). For
instance, genetic engineering of MSCs has been employed to
overexpress key chemokine receptors such as CXCR4 (Cheng
et al., 2008) and CCR1 (Huang et al., 2010), and growth factor
preconditioning has been used (Hahn et al., 2008; Son et al.,
2006) to increase MSC homing to injured myocardium and
improve cardiac performance. In addition, bioengineering
approaches offer significant potential for chemically modifying
the hMSC surface to improve homing to sites of inflammation
(Sarkar et al., 2011b). Interestingly, MSCs secrete mobilizing
factors such as HGF, LIF, SDF-1, SCF, and VE-Cadherin
(Table S1) and thus, optimizing the transplanted MSC secre-
tome could also be beneficial for mobilization and homing of
host MSCs.Striking a Balance between Positive and Negative
Factors
Some factors in the MSC secretome, depending on the concen-
tration and release kinetics, may exert inhibitory effects on the
cardiac microenvironment, such as apoptosis of cardiomyo-
cytes, inflammation, pathological remodeling, or scar formation.
For instance, the TGF-b class of cytokines secreted from
poly(I:C)-treated, TLR3-primed hMSCs (Waterman et al., 2010)
are known to mediate pathological remodeling during MI and
their repressed secretion likely results in decreased collagen
deposition. MMP-2, a factor known tomediate ECMdegradation
during MI (Matsumura et al., 2005) resulting in pathological
remodeling via cardiomyocyte anoikis and macrophage infiltra-
tion, is endogenously secreted by hMSCs, and the activity of
hMSC-secreted MMP-2 can be inhibited by treating hMSCs
with TNF-a or hypoxia (Lozito and Tuan, 2011). Additionally,
MSC-secreted factors such as MMP-9 and IL-6, responsible
for pathological remodeling and proinflammatory responses,
respectively, should ideally be maintained at minimum levels
because these factors are upregulated in themyocardium during
MI (Biswas et al., 2010; Liu et al., 2011). Inhibition of negative
factors using antagonists (produced by MSCs) such as TIMP-1
(for MMP-9) and IL-10 (for IL-6) via either intracellular or extracel-
lular targets is one possible strategy for alleviating these effects.
Hence, it seems important to not only consider upregulating
anti-inflammatory or proangiogenic factors, but also to strive
to achieve an appropriate balance between stimulatory and
inhibitory factors produced by MSCs as depicted in Figure 1B.
In addition to achieving such a balance through iterative in vitro
experiments, ultimately the response will need to be preserved
following in vivo transplantation, perhaps through bioengi-
neering approaches (Sarkar et al., 2011a) and strategies illus-
trated in Figure 2.
Bench to Bedside: Practical Considerations for
Harnessing the MSC Secretome in Clinical Settings
The first clinical trial for AMI using hMSCs was a randomized,
double-blinded, placebo-controlled, dose-escalation study of
allogenic hMSCs (Prochymal, Osiris Therapeutics, Inc., Balti-
more,MD) (Hare et al., 2009). This study demonstrated the safety
of intravenous hMSC transplantation and provisional efficacy
(increased left ventricular ejection fraction [LVEF], reduced
cardiac arrhythmias, and reverse remodeling compared to
placebo) in AMI patients. Results from a phase II multicenter,
randomized, double-blind, placebo-controlled study to evaluate
Prochymal for safety and efficacy are anticipated in the near
future. The ongoingMSC-based trials for treatment of cardiovas-
cular diseases listed in Table 1 reveal an interesting trend in trial
designs, in which MSC paracrine mechanisms for improving
angiogenesis, cardio-myogenesis, stimulating endogenous
cardiac progenitors, and inhibiting remodeling have been high-
lighted as the primary modes of action. The interim follow-up
of two ongoing trials (NCT00677222 and NCT00721045) has
reported significant improvement in cardiac functions such as
LVEF and stroke volume, and a reduced number of patients
with major adverse cardiac events. Nevertheless, the perfor-
mance of MSCs in these clinical trials has not uniformly met
expectations, because positive results and statistical sig-
nificance were not achieved for all output measures, theCell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc. 247
Figure 2. A Proposed Engineering Solution
for Sustaining a Customized MSC
Secretome In Vivo and Facilitating
Cardiovascular Repair
Bioengineering strategies may be employed to
control and sustain the expression of the
customized MSC secretome through smart-
biomaterials-based, intra- and/or extra-cellular,
controlled release of stimulating molecules.
MSCs, either as single cells or aggregates, may be
systemically infused or locally transplanted to
facilitate cardiovascular repair with greater control
over cell fate and function.
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formulations are not fully optimized in terms of delivery methods,
secretome composition, cell survival/persistence, and engraft-
ment efficiency. Furthermore, little is known regarding the effect
of time of MSC administration on the prevention of cardiomyo-
cyte necrosis/apoptosis, which develops rapidly within 30 min
to 12 hr following the onset of MI (Schoen, 2007).
Direct involvement of factors secreted by MSCs in cardiac
functional improvement in humans is difficult to demonstrate.
Although identification and quantification of the myocardial
tissue concentrations of paracrine factors is not feasible, their
plasma levels could be indicative of their presence. Future clin-
ical trials should therefore incorporate systematic analysis of
the patient plasma not only to elucidate the presence/absence
of MSC-secreted paracrine factors but also to investigate
whether the impact on host tissue is sustained after elimination
of the transplantedMSCs. Although it is challenging to determine
whether paracrine factors originate from host cells or trans-
planted MSCs and to characterize their impact on regulating
cytokine expression from host cells (new techniques may be
required), a comparative analysis of the patient plasma before
and after MSC treatment may provide some insight (and be
useful for establishing biomarkers forMSC therapy). Approaches
for upregulating specific paracrine factors may help to elucidate
(indirectly) mechanisms responsible for the MSC-mediated
clinical outcomes (Mirotsou et al., 2007). Although some studies
have shown that endocrine activity of dying MSCs can promote
regeneration of distant ischemic tissues (Lee et al., 2009), the
impact of the MSC secretome on cardiovascular repair can likely
be improved through enhancing the survival of the transplanted
cells and improving their homing to the target site (Karp and
Leng Teo, 2009). Hence, MSC modifications that lead to im-
proved survival and facilitate a sustained and regulated secre-
tome should be considered.
‘‘Cell-free’’ Therapy: An Alternate to Using MSCs?
Several clinical trials have investigated cytokine therapy
approaches for treating cardiovascular diseases (Beohar et al.,
2010), and this is further motivated by the improvement in
cardiac function seen in preclinical studies from administration
of MSC-conditioned medium (Gnecchi et al., 2006). For ex-
ample, VEGF protein delivery has been shown to improve
angiogenesis in coronary artery disease patients (Henry et al.,248 Cell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc.2003). G-CSF, a cytokine known to
mobilize progenitor cells from the bone
marrow, was subsequently explored in
a series of AMI clinical trials. Despiteevidence of safety and feasibility of G-CSF administration in MI
patients (Valgimigli et al., 2005), treatment with G-CSF with 5
or 10 mg/kg/day via subcutaneous injection 5 to 6 days after
percutaneous coronary intervention (PCI) did not yield any sig-
nificant increase in LVEF (Engelmann et al., 2006; Ripa et al.,
2006). Other cytokines such as GM-CSF, EPO, and IGF-1 have
also been tested in clinical trials of cardiovascular diseases
(Beohar et al., 2010). To date, single cytokine therapy trials
have not met expectations, and there are several possible ex-
planations for why this is the case. Multiple cytokines/growth
factors may need to be administered simultaneously at different
concentrations and time points to act synergistically to achieve
a therapeutic effect. Side effects due to high doses of certain
cytokine/growth factors, which may be required due to chal-
lenges in protein delivery, can lead to the formation of aberrant
and leaky vessels (Carmeliet, 2005), hypotension (Henry et al.,
2001), and tumor angiogenesis (Epstein et al., 2001). Controlling
the local levels of exogenously delivered cytokines is critical
given limitations of pharmacokinetics and stability of proteins
in vivo. For instance, intramyocardially delivered, protease-
resistant SDF-1 was undetectable after 1 day, yet controlled-
release, protease-resistant SDF-1 tethered to self-assembling
peptide nanofibers was retained within the myocardial tissue
even at day 7 in a rat MI model, and this persistence translated
into significant improvement in capillary density and LVEF.
Controlled local release of SDF-1 also led to a substantial
increase in c-kit+ cell recruitment into the myocardium (Segers
et al., 2007). Recombinant periostin exhibited enhanced tissue
distribution and persistence via controlled local delivery from
Gelfoam patches in a rat MI model (Ku¨hn et al., 2007). Compared
to the delivery of single growth factors or cytokines, the use of
cells such as MSCs to supply these agents offers significant
potential for sustained pharmacokinetics, synergy from multiple
factors, and an opportunity for systemic infusion, which is less
invasive than local injection and thus amenable to repeated
dosing.
Secrets of the MSC Secretome: Underlying Signaling
Pathways
Elucidation of the molecular pathways mediating MSC secre-
tome expression is a crucial step toward improving our under-
standing of the secreted factor profile and its clinical utility.
Table 1. Ongoing MSC-Based Clinical Trials for Cardiovascular Diseases Registered at clinicaltrials.gov
Clinical Trial ID Phase Condition
No. of
Patients
Outcome
Measure Cell Delivery Route Basis of Trial Design
NCT01394432 III AMI 50 LVSV endocardial reduction in scar formation and increased
reverse remodeling
NCT00877903 II MI 220 ESV, LVEF,
infarct size
intravenous improvement in myocardial remodeling
and reduction in incidence of CHF
NCT00790764 II SCI 60 safety intracoronary and
transendocardial
development of mature and stable vessels
and improved cardiac function via
combinatorial effect of BM-MNCs and MSCs
NCT00555828 I/II MI 25 safety, feasibility transendocardial transdifferentiation of mesenchymal precursor
cells (MPCs) into cardiomyocytes
NCT00677222 I AMI 28 safety, efficacy space surrounding
target vessel
(perivascular)
improvement in cardiac function via
MSC paracrine actions
NCT01291329 II AMI 160 myocardial
metabolism,
perfusion, LVEF
intracoronary transdifferentiation of MSCs into
cardiomyocytes
NCT00768066
(TAC-HFT)
I / II IHF 60 safety transendocardial stimulation of endogenous cardiac stem
cells by the transplanted MSCs
NCT00644410 I / II CHF 60 LVEF intramyocardial development of new myocardium
and blood vessels
NCT00587990
(PROMETHEUS)
I / II LVD 45 safety, LVEF,
infarct size, ESV
intramyocardial combinatorial effects of bypass surgery
and MSC transplantation
NCT00721045 II HF 60 safety, efficacy transendocardial MPC-induced large blood vessel formation
and cardiac repair
NCT00418418 II MI 60 LVEF, safety intramyocardial combinatorial effects of bypass surgery
and MSC transplantation
NCT00883727 I / II MI 20 myocardial
perfusion,
infarct size
intravenous transdifferentiation of MSCs into cardiomyocytes
and production of new blood vessels
NCT01087996
(POSEIDON)
I / II LVD, MI 30 safety, efficacy transendocardial neo-myogenesis induced by transplanted
allogenic and autologous MSCs
NCT01076920
(MESAMI)
I / II MI, LVD 10 safety, efficacy transendocardial transdifferentiation of MSCs to produce
new blood vessels
NCT01449032 II CMI 60 safety, efficacy not specified angiogenesis
NCT01442129 II HF 30 safety, efficacy intramyocardial MPC-induced angiogenesis via paracrine
signaling combined with LVAD implantation
NCT01392625 I / II NDC 36 safety, efficacy transendocardial neomyogenesis via MSC-CSC interaction
NCT01270139
(NANOM)
I / II CAD 180 plaque volume stenting functional restoration of blood vessels via
nanoburning and MSC paracrine effects
NCT01436123
(NANOM2)
I CAD 120 plaque volume stenting reduction of plaque via paracrine signaling in
combination with burning effects from Si-Fe NPs
LVSV, left ventricular systolic volume; SCI, severe coronary ischemia; IHF, ischemic heart failure; CHF, congestive heart failure; LVD, left ventricular
dysfunction; ESV, end systolic volume; LVEF, left ventricular ejection fraction; CMI, chronic myocardial ischemia; LVAD, left ventricular assist device;
NDC, nonischemic dilated cardiomyopathy; CAD, coronary artery disease.
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signaling mechanisms involved in the expression of the MSC
secretome, a wide array of signaling pathways have been
implicated in paracrine-mediated cardiac repair by MSCs
(Gnecchi et al., 2008).
The PI3K/Akt pathway is believed to be involved in the pro-
duction and secretion of paracrine factors by rMSCs (Gnecchi
et al., 2005, 2006). Genetically modifying rMSCs to overexpress
the Akt gene resulted in the upregulation of the Akt target genes
VEGF, FGF-2, IGF-1, HGF, and Thrombospondin-4 (Gnecchiet al., 2006). PI3K signaling and ERK1/2 signaling have also
been implicated in VEGF production by mMSCs in response to
exogenous IL-6 in vitro (Herrmann et al., 2011), although it is
unclear whether the effect is solely from the exogenous IL-6
treatment because mMSCs constitutively secrete IL-6. In
another study, AngII-stimulated VEGF expression and secretion
from rMSCs was mediated by ERK1/2 and the Akt pathway via
angiotensin II type 1 (AT1) receptor in vitro (Shi et al., 2009).
Another important signaling pathway is the p38 mitogen-
activated protein kinase (p38 MAPK), which mediates hMSCCell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc. 249
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a-induced) response, and led to increased in vitro production
of VEGF, HGF, and IGF-1 by hMSCs (Wang et al., 2006). The
p38 MAPK pathway, along with MEK and PI3K, has also been
implicated in mediating TGF-a-induced in vitro HGF production
in hMSCs via EGF receptor (EGFR) (Wang et al., 2009). The
involvement of p38 MAPK in TGF-a-induced in vitro VEGF
production in mMSCs via EGFR (Herrmann et al., 2010) and
serum-free-medium-induced in vitro production of IL-6, IL-8,
and CXCL1 (Yew et al., 2011) in hMSCs have also been reported.
The JAK-STAT cascade is thought to be a central regulatory
pathway in MSC paracrine factor expression. For instance,
STAT3 and p38 MAPK were shown to mediate the TNF-
a-stimulated VEGF production by mMSCs in vitro (Wang et al.,
2007). However, whether VEGF production is independently
controlled by p38 MAPK and STAT3 or via a crosstalk between
these pathways is not yet clear. STAT3 and MAPK were also
activated by treating hMSCs with IL-6, leading to improved
in vitro hMSC migratory potential, likely via paracrine activity
(Rattigan et al., 2010). In another study, knockout of toll like
receptor-4 (TLR4) in mMSCs resulted in an increased in vitro
secretion of angiogenic factors and chemokines and decreased
secretion of inflammatory chemokines via STAT3 activation
(Wang et al., 2010), further highlighting the role of STAT3
signaling in the MSC secretome expression. The transcription
factor GATA-4 has also been implicated in the increased rMSC
production of angiogenic paracrine factors (VEGF, IGF-1, and
bFGF) and was shown to possess antiapoptotic effects on
MSCs under stress via GATA-4 overexpression (Li et al., 2010).
The transcription factor nuclear factor-kB (NF-kB) is consid-
ered a central regulator of stress response and a key mediator
of immune responses, regulating the expression of more than
150 target genes (Pahl, 1999) that code for cytokines, chemo-
kines, growth factors, cell adhesion proteins, and cell surface
receptors. NF-kB function in hMSCs has been investigated
under stress conditions, such as TNF-a, lipopolysaccharide
(LPS), and hypoxia (Crisostomo et al., 2008), and its activation
was implicated in the increased in vitro production of several
growth factors, such as VEGF, FGF-2, and HGF, by hMSCs in
response to stress conditions. The involvement of NF-kB via
TLR4 receptor activation is demonstrated in the production of
prostaglandin E2 in hMSCs upon treatment with LPS, leading
to a reduction in inflammation in a cecal ligation and sepsis
(CLP) model in mice (Ne´meth et al., 2009). Recently, more
evidence of the involvement of NF-kB signaling in rMSC para-
crine factor expression has been reported (Afzal et al., 2010).
Diazoxide (DZ), a KATP-channel-opening small molecule,
concomitantly augmented the phosphorylation of PI3K/Akt,
glycogen synthase kinase 3b (GSK3b), and NF-kB in rMSCs,
resulting in elevated expression levels of growth factors such
as IGF, bFGF, HGF, Ang-2, and VEGF in vitro.
Although the mechanistic studies conducted so far have
provided some key insights, a more comprehensive under-
standing of the signaling networks responsible for the unique
MSC secretome is still required. The network of signaling path-
ways involved in constitutive expression of the MSC secretome
has not been elucidated yet, but clearly there is a major role for
stress signaling that may represent the MSCs’ ability to sense
and respond to specific stimuli and allow the cells to cope with250 Cell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc.changing environmental conditions. A comparative study of
evolutionarily conserved signaling pathways that mediates
MSC secretome expression could be informative. The activa-
tion/inhibition of multiple pathways could be essential to obtain
an appropriately customized balance of secreted factors. The
interaction of kinases with transcription factors is also not well
understood. Additionally, two or more transcription factors, for
example GATA and STAT, could also interact at the transcrip-
tional level to mediate paracrine secretion (Wang et al., 2005).
Considering the complexity of signaling networks, a holistic
approach must be used to establish the specific role of recep-
tors, kinases, and transcription factors in the MSC secretome.
Such an approach could provide a useful axis for enhanced
control over the secretome profile, leading to the development
of precisely regulated MSC therapies.
The Secretome Switches: Preconditioning Strategies
for Stimulating MSC Paracrine Secretion
A number of preclinical studies have focused on transplanting
MSCs into the infarcted heart with the hope that relevant
signaling cues from the injury would regulate the MSC secre-
tome (Iso et al., 2007; Lee et al., 2009; Nagaya et al., 2005; Shab-
bir et al., 2009). However, most of the signaling molecules (such
as TNF-a, IL-6, IL-1b, IFN-g, MCP-1, Fractalkine, and others)
secreted by macrophages, monocytes, fibroblasts, and cardio-
myocytes during MI are transient. For example, the TNF-a level
in the myocardium of rat infarcted hearts peaked at 7–8 days
after MI, followed by a decline to basal level in the plasma within
48 hr (Berthonneche et al., 2004; Moro et al., 2007). Thus, even
though these signaling molecules could produce a brief exten-
sion of MSC survival and an improved response to the highly
dynamic and heterogeneous signaling cues during MI, they are
unlikely to achieve long-lasting, controlled MSC paracrine
action. Hence, other longer-lasting means of improving trans-
planted MSC function through extending MSC survival or via
improved control of the secretome composition have been
investigated. Most of these strategies are performed ex vivo
and are referred to as preconditioning strategies.
Physiological Preconditioning
Subjecting MSCs to physiological conditions of hypoxia (<5%
O2) and anoxia in vitro and in the ischemic heart has been
reported to improve the survival of transplanted MSCs, cardio-
myocytes, and endothelial cells via paracrine effects. For
example, Kinnaird et al. demonstrated a significant increase
(>1.5-fold) in the secretion of several arteriogenic cytokines,
including VEGF, bFGF, PlGF, and TGF-b, after subjecting
hMSCs to 72 hr hypoxia compared with normoxic conditions
(Kinnaird et al., 2004a). However, the increased levels of VEGF
and bFGF in hMSC-conditioned medium could only partially
account for the improved endothelial cell proliferation response
in vitro. A systematic gene expression analysis showed that at
least 165 genes, including vegf, egf, and mmp-9, were upregu-
lated >3-fold in rMSCs following 24 hr hypoxic preconditioning
(Ohnishi et al., 2007). However, this study did not report secreted
protein levels and related functional assays to establish a corre-
lation between secretion levels and function. Moreover, there is
considerable variation between studies in terms of the hypoxia
exposure time and the resulting secretion levels of paracrine
factors. It is also not clear how long hypoxia preconditioning
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another in vitro model for ischemia, has also been shown to
induce secretion of angiogenic factors by hMSCs (Oskowitz
et al., 2011), the observed effect could have been due to differ-
ences in cell proliferation rates. In general, physiological precon-
ditioning via hypoxia exposure inducesMSCs to activate survival
pathways and secrete factors to counteract hypoxic effects.
However, given its short duration, it is unclear if this transient
response could produce a clinically relevant outcome.
Genetic Manipulation
MSCs can also be engineered with transgenes for conditional
gene expression (typically a single gene) with the aim of
improving cell survival and controlling the MSC secretome
posttransplantation. Transplanting Akt1-transfected rMSCs in-
tramyocardially in rat MI models was advantageous and
restored a 4-fold increase in myocardial volume (Mangi et al.,
2003), but whether this effect was a result of improved rMSC
survival or paracrine effects (or both) was not investigated.
Akt-overexpressing rMSCs showed upregulated transcript
levels of cytoprotective genes vegf, bfgf, hgf, igf1, and tb4
in vitro, suggesting their involvement in mediating the early
improvement in cardiac function seen in a rat MI model,
including significant reduction in infarct size and improved
(1.42-fold versus control) ventricular function <72 hr after
rMSC transplantation (Gnecchi et al., 2006). Akt overexpression
in mMSCs substantially upregulated SFRP2, a paracrine factor
that was demonstrated to be responsible for the improved car-
diomyocyte survival and reduced infarct size (3-fold versus PBS
control) following transplantation (Mirotsou et al., 2007). MSCs
have also been genetically modified to overexpress factors
such as VEGF (Yang et al., 2010), IGF1 (Haider et al., 2008),
and SDF-1 (Tang et al., 2010). When harnessed for cardiovas-
cular applications, these modified MSCs improved angiogen-
esis, LVEF, c-kit+ and CD31+ cell mobilization, and contractile
function, and reduced LV remodeling effects, primarily through
paracrine actions. Overexpression of the transcription factor
GATA-4 (Li et al., 2010) and knockout of TLR4 (Wang et al.,
2010) in MSCs resulted in the increased secretion of VEGF.
However, these manipulations also resulted in increased (for
MSC-GATA-4) or decreased (TLR4KO-MSC) IGF-1 secretion
levels versus wild-type MSCs; the discrepancy is likely due to
the genetic targets manipulated and MSC sources (rMSCs for
GATA-4 and mMSCs for TLR4 knockout). Therefore in these
two studies, the role of IGF-1 in the observed cardioprotective
effects in rat MI models is not clear. In general, genetic
approaches could be harnessed to directly or indirectly upregu-
late specific MSC paracrine factors via upregulation of estab-
lished target genes, even though overexpression of certain
genes could lead to undesired effects (Fierro et al., 2011).
Nonviral modifications should be sought due to the limitations
of viral approaches, including the potential for insertional muta-
genesis and increased regulatory hurdles. Furthermore, while
there have been many attempts to improve MSC function via
genetic manipulation, aside from immunomodulatory factors
(e.g., IL-10, IDO, and PGE2) and proangiogenic factors (e.g.,
VEGF), strong candidates worthy of future pursuit have yet to
be identified. The lack of such candidates is probably due to
an absence of deep understanding of the underlying pathways
and a lack of replicated studies by multiple laboratories.Molecular Preconditioning Using Proteins
Cytokines, chemokines, and growth factors represent key
signaling cues during MI (Debrunner et al., 2008) and hence
have been used to control MSC paracrine secretion in vitro
(Croitoru-Lamoury et al., 2007). Stimulation of MSCs with
TNF-a (50 ng/ml) for 24 hr (Wang et al., 2007), SDF-1
(50 ng/ml) for 1 hr (Pasha et al., 2008), or TGF-a (250 ng/ml)
and TNF-a (50 ng/ml) for 24 hr (Herrmann et al., 2010) resulted
in increased production of VEGF in the conditioned medium
compared with unstimulated MSCs. Table 2 highlights the avail-
able in vitro data including peak concentration of the secreted
paracrine factors as a function of dose and duration of stimula-
tion. So far, however, these studies have not characterized the
impact of time and/or dose of stimulation on paracrine factor
secretion and cardiac functional improvement in vivo, which
would be important for assessing the potential utility in clinical
settings.
In an attempt to exploit synergistic effects, cocktails of cyto-
kines, conditioned medium, or serum have been employed to
stimulate MSCs. For example, when transplanted into NOD/
SCID mice, hMSCs stimulated in vitro by a cytokine cocktail
(Flt-3 ligand, SCF, IL-6, HGF, and IL-3) expressed higher levels
of CXCR4 mRNA and showed improved SDF-1-induced migra-
tion capacity (>20-fold versus unstimulated MSCs) to the bone
marrow 24 hr after transplantation and enhanced homing
(>2-fold versus unstimulated MSCs) to the bone marrow of irra-
diated mice 2–6 months after transplantation (Shi et al., 2007). In
another study, hMSCs exposed to LPS-stimulated rat serum for
24 hr responded by secreting higher levels (4.5-fold versus
normal serum) of sTNFR1 (Yagi et al., 2010). Importantly, intra-
muscularly injected serum-stimulated hMSCs attenuated
inflammation via paracrine actions of sTNFR1 and other anti-
inflammatory cytokines. Another approach that has been tested
is coculture of MSCs with other cell types. For example, TSP-1
was upregulated in rMSCs cocultured with retinal ganglion cells
(RGCs) (Yu et al., 2008). Block et al. cocultured hMSCs with
apoptotic fibroblasts for 48 hr, thus exposing the hMSCs to
apoptotic cytokines (Block et al., 2009) and leading the stimu-
lated hMSCs to secrete STC-1, a peptide with antiapoptotic
effects on lung epithelial cells. Clearly more comprehensive
studies are required to examine the impact of protein-based
preconditioning regimens on MSC-based therapeutic ap-
proaches, including applications for cardiovascular diseases. A
better understanding of how the cytokines expressed in cardiac
ischemic or inflammatory microenvironments in vivo modulate
MSCs to exert a therapeutic effect could be very helpful for
developing more effective protein-based preconditioning
approaches.
Pharmacological Preconditioning
Another promising approach for pretreating MSCs prior to
transplantation involves small molecules, which have the advan-
tages of ease of synthesis, cost effectiveness, and specific
actions on cellular signaling. The availability of small molecule
libraries enables high throughput screening to identify molecules
for modulating specific cellular functions. However, there is
currently no clearly demonstrated evidence of efficient MSC
secretome regulation by small molecules. Some studies have
suggested that small molecules can increase rMSC survival
under ischemic conditions and can bring about a moderateCell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc. 251
Table 2. Representative Time- and Dose-Dependent Release Profiles of Paracrine Factors from Preconditioned MSCs In Vitro and
Related Functional Improvements
Stimulating
Molecule
Dose and
Time of
Stimulation
Paracrine
Factors
Upregulated
Peak
Concentrationa
(ng/ml)
Fold Change in
Concentration versus
Nonconditioned MSCs Functional Improvements Reference
TNF-a 0.1 0.1,
0.5, 2, 5,
10 ng/ml for
0, 6, 12, 24
and 48 hr
IL-6 19.0 15 dose-dependent improvement
in monocyte migration upon
treatment with varying doses
of TNF-a-stimulated,
MSC-conditioned medium
Lee et al., 2010
(as above) IL-8 38.0 30 (as above) (as above)
(as above) MCP-1 18.0 15 (as above) (as above)
(as above) CXCL6 0.3 30 (as above) (as above)
TNF-a 100 IU/ml for
6, 24, 72 hr
IL-8 100.0 6 enhanced migration of
preconditioned hMSCs
in response to chemokines
such as SDF-1
Croitoru-Lamoury
et al., 2007
(as above) MCP-1 75.0 3.75 (as above) (as above)
IFN-b 100, 1000,
2000 UI/ml for
6, 24, 72 hr
MCP-1 10.0 4 (as above) (as above)
100, 1000,
2000 UI/ml
for 6, 24, 72 hr
IP-10 0.42 4 (as above) (as above)
LPS 0, 0.01, 0.1,
1, 10 mg/ml
for 48 hr
VEGF 1.35 pg/105 cells 2 enhanced VEGF levels in
myocardium and improved
survival of transplanted mMSCs
Yao et al., 2009
aPeak concentrations have resulted from the duration and dose of stimulation (in italics) in the respective studies.
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intracellular levels of rMSC-expressed paracrine factors (Afzal
et al., 2010; Mias et al., 2008; Wisel et al., 2009). In addition to
small molecules, LPS treatment enhanced paracrine factor
secretion (dose dependently) from mMSCs (Table 2), thereby
improving survival of transplanted mMSCs (>1.5-fold versus
control) via increased VEGF levels in the myocardium (>2.2-
fold versus control) observed 3 weeks after cell transplantation
in rat infarct hearts (Yao et al., 2009). If we are looking to apply
preconditioning with agents such as LPS that would exert a
detrimental systemic impact on the host, it will be important
to minimize the concentration delivered with MSCs after
preconditioning to prevent pharmacological effects on the host.
Preconditioning through Cell-Cell Interactions
and Physical Preconditioning
Promotion of cell-cell interactions between MSCs can also
have a profound impact on the MSC secretome. For example,
Potapova et al, developed a simple strategy of organizing
hMSCs into 3D spheroids of varying sizes using a hanging
drop method to increase secretion levels of paracrine factors
(Potapova et al., 2007). Using this approach, they observed
high concentrations (5–20 times) of IL-11, as well as the proan-
giogenic cytokines VEGF, bFGF, and angiogenin, in the
conditioned medium from hMSC spheroids compared with
conditioned medium from hMSC monolayers. The onset of
hypoxia in the core of the cell aggregates was proposed to be
the driving force for the increased secretion levels. A similar
study demonstrated that culturing hMSCs as 3D spheroids
restored CXCR4 functional expression, demonstrated by 35%252 Cell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc.of the cells derived from day 3 spheroids being CXCR4+ (Pota-
pova et al., 2008). In a separate study, hMSC spheroids grown
in suspension cultures were found to secrete 60-fold more
TSG-6 protein than adherent monolayered hMSCs (Bartosh
et al., 2010). More importantly, the size of the spheroid-derived
cells was significantly smaller than hMSCs from adherent
cultures, allowing them to more readily escape lung entrapment
in vivo following systemic infusion. Another approach for
increasing secretion of paracrine factors involves culturing
monolayers of rat-adipose-tissue-derived MSC sheets, pre-
pared by incubating rMSC monolayers within temperature-
responsive dishes at 20C for about 40 min and detaching
them into monolayers of rMSC sheets (Miyahara et al., 2006).
Although promising, it is unclear how MSC preconditioned by
promoting assembly into 3D aggregates or 2D monolayers will
retain their secretion profiles following transplantation as single
cells or 2D/3D constructs.
Microenvironmental cues such as shear stress and substrate
compliance have also been used to control MSC paracrine
activity. For example, human adipose-tissue-derived MSCs
subjected to laminar shear stress (10 dyn/cm2 up to 96 hr)
secreted higher amounts of VEGF (2-fold versus static hMSCs)
(Bassaneze et al., 2010). In another study, hMSCs grown on
hydrogel substrates mimicking hard and soft tissue secreted
differential levels of VEGF, IL-8, and uPA for up to 14 days
(Seib et al., 2009).
Summary of MSC Preconditioning Strategies
Preconditioning via controlled cell-cell interactions has shown
promise for increased secretion of pertinent factors, but may
Table 3. Unaddressed Critical Issues for Current MSC Preconditioning Strategies
Preconditioning Mode Issues Recommended Actions
Physiological highly varied hypoxia exposure time (4 to 72 hr);
nonspecific activation of signaling pathways
leading to uncontrolled secretome; duration of
preconditioning effects is not well understood
optimize hypoxia exposure time to maximize MSC survival;
investigate different modes of hypoxia such as brief exposures
mimicking ischemic preconditioning to better understand effect of
hypoxia on MSC survival and sustained paracrine action in vivo
Genetic activates single target gene; gene expression
levels do not correlate with the concentration
of secreted factors; limited control over local
pharmacokinetics of expressed protein; limited
understanding of the temporal expression
of proteins; safety posttransplantation
multiple gene activation leading to expression/release of
a cocktail of proteins that act in synergy; overexpression studies
to establish correlation between gene and protein expression
levels; optimize the mode of gene and cell delivery (e.g., combine
with a biomaterials approach); carefully examine the literature for
comparable approaches, perform relevant safety analysis in
animal models, and consider nonviral approaches
Protein/cytokine effects of incubation time and protein
concentration on promoting sustained effects
are not well understood; high concentrations
required to stimulate the MSC due to
transport limitations
kinetic studies of pathway activation and factor release
in vitro and in vivo; transport limitations could be overcome
by intracellularly or extracellularly controlled delivery
of proteins/cytokines using polymeric micro/nano-systems
Pharmacological effects of incubation time and drug
concentration on promoting sustained effects
are not well understood; agents may exhibit
a negative impact on the host
kinetic studies of pathway activation and factor release in vitro
and in vivo; identifying highly specific activators/inhibitors;
ensuring concentration of agents is minimized in cell
suspension prior to transplantation
Cell-cell interaction the mechanism by which 3D MSC aggregates
retain high secretome expression is not clear
perform studies to reveal the involvement of MSC adhesion
ligands or ECM in activating specific signaling pathways
Physical the signaling pathways activated by physical
stimuli are not well understood
elucidation of the mechanisms by which physical stimuli
influence the MSC secretome; kinetic studies of pathway
activation and factor release both in vitro and in vivo
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the secretome. Although physiological and molecular (cytokine/
small molecule) preconditioning is simple and more targeted,
the impact is transient due to self-regulatory mechanisms, and
it is likely that these approaches will have a limited duration of
impact posttransplantation. Genetic manipulation has the
advantage of a sustained response; however, it is often limited
to a single target gene and clinical translationmay be challenging
due to higher regulatory hurdles if viruses are utilized. Regard-
less of the preconditioning approach applied, MSCs typically
exhibit limited persistence following transplantation, and thus,
achieving sustained secretion following a single MSC dose will
require new techniques to boost MSC survival. While a proof of
concept for this has been achieved using virally transfected
MSCs (Mangi et al., 2003; Mirotsou et al., 2007), much-desired
nonviral approaches are currently being developed to achieve
rapid and safe translation (Yang et al., 2010). Coadministration
of drugs such as Atorvastatin with MSCs may also improve the
cardiac microenvironment after MI to achieve better survival
of the implanted MSCs (Yang et al., 2008). Likewise, immunose-
lection aimed to enrich the cell population with stromal precursor
antigen-1 (STRO-1)+ mesenchymal progenitor cells (MPCs)
could also improve cardiovascular paracrine activity (Psaltis
et al., 2010).
While the majority of preconditioning strategies promote
expression/secretion of a narrow class of cytokines that are
constitutively secreted by MSCs at basal levels, it would be
useful to examine if preconditioning of MSCs could be utilized
to express therapeutic factors that are not secreted by MSCs
under basal conditions. Despite the promise of several precondi-
tioning strategies, there are critical unmet needs and uncer-tainties yet to be addressed, and these are listed and discussed
in Table 3. However, better control over the MSC secretome
posttransplantation could be achieved through customization
strategies as depicted in Figure 1, which could be translated
into clinics via engineering the MSC secretome using controlled
release approaches as depicted in Figure 2.
Summary and Perspectives
Harnessing the MSC secretome for cardiovascular repair seems
in principle to have significant clinical potential given the innate
immunomodulatory and trophic properties of many of the factors
secreted by MSCs. While some groups are directly employing
MSC-derived therapeutic paracrine factors in the absence of
cells, approaches employing a cocktail of secreted factors will
require GMP manufacturing protocols with reproducible
batch-to-batch secretome properties (that may be impacted
by several factors including the MSC donor), and will require
a defined regulatory pathway. Also, in general, cytokine-based
approaches have not performed well in clinical trials due to
inherent limitations in tissue transport, pharmacokinetics, and
protein stability in vivo. These issues can likely be addressed
for individual cytokines through the development of appropriate
controlled release strategies; however, delivery approaches for
complex cocktails of therapeutic agents, such as the isolated
MSC secretome, will be a significant challenge.
The majority of MSC-based clinical trials for cardiovascular
therapy focus on the potential benefits of the immunomodulatory
and trophic properties of MSCs rather than their potential to
generate new tissues directly. Although it is still early to draw
conclusions, the available trial results are not as promising as
has been hoped based on preclinical animal studies. This relativeCell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc. 253
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formulations and poor understanding of how MSCs induce
cardiovascular repair. Importantly, signaling pathways medi-
ating the expression and secretion of relevant MSC factors and
the mechanism of how they synergistically impact cardiovas-
cular repair are beginning to be elucidated. Nevertheless, the
relevance of the MSC secretome to the treatment of cardiovas-
cular disease is still controversial, and hence, identifying and
characterizing additional MSC-secreted factors that can either
facilitate cardiomyogenesis or activate endogenous CSCs
seems crucial. The molecular events responsible for altering
the MSC secretome in vivo, as a function of microenvironmental
stimuli, remain elusive. Clear understanding of the in vivo MSC
secretome and its potential functional benefits is still far from
being resolved, and this is a key prerequisite to harnessing this
potentially powerful tool for maximal therapeutic benefit.
The currently favored approach for regulating cells after
transplantation involves preconditioning MSCs with the aim of
improving homing, survival, and secretome control. Clarifying
the underlying signaling pathways should enable development
of more effective preconditioning regimens to activate/inhibit
relevant pathways to maximize the therapeutic effect. As the
biology mediating the therapeutic benefit of MSC secretome
becomes more defined, targeted preconditioning and genetic
manipulation approaches will likely be useful to enhance the
therapeutic benefit.
Looking to the future, state-of-the-art bioengineered materials
offer the potential for enhanced control of cells and presentation
of MSC secretome after transplantation. For example, paracrine
factors from hypoxia-conditioned MSCs bound to nano-struc-
tured materials have yielded significant hemodynamic functional
preservation within an infarcted heart model (Webber et al.,
2010), and the transplantation of cells such as CPCs with immo-
bilized IGF-1 on nano-fibers exhibited dual effects from IGF-1-
mediated activation of resident cardiac cells and protection of
transplanted CPCs (Padin-Iruegas et al., 2009). Cardiac-specific
decellularized matrices (Godier-Furne´mont et al., 2011; Singelyn
andChristman, 2010) and biopolymers (Danoviz et al., 2010) may
also serve as injectable biomaterials to deliver MSCs in a more
sustainable and effective manner. Recently, we employed a
polymer-based controlled drug release strategy to program
MSC fate through engineered intracrine-, paracrine-, and endo-
crine-like mechanisms (Sarkar et al., 2011a). In addition to
controlling cell fate, this biomaterials approach provides an
opportunity to control the MSC secretome posttransplanta-
tion—for example, through sustained intracellular release of
small molecules that target specific pathways. As an alternative
to transplantation of single-cell suspensions, the MSC secre-
tome may also be exploited through transplantation of engi-
neered MSC spheroids that have shown potential for enhanced
paracrine levels in vitro. Given the relatively harsh microenviron-
ment presented at a site of injury or ischemia, it may be of interest
to transplant MSCs at a distant site where paracrine factors can
reach damaged heart tissue through systemic endocrine effects
(Lee et al., 2009). Although challenges remain, harnessing the
MSC secretome for meaningful therapeutic outcomes will likely
be realized in the near future by capitalizing on customization
strategies as depicted in Figure 1 and Figure 2 for controlling
and sustaining the MSC secretome posttransplantation.254 Cell Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc.SUPPLEMENTAL INFORMATION
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